Opioid Agonist Treatment

PROFESSIONAL PRACTICE POLICY-66: OPIOID AGONIST TREATMENT

Professional Practice Policy-66: Opioid Agonist Treatment sets out requirements for safe dispensing of drugs used to treat opioid use disorder. This policy has been updated to align with the new Provincial Guidelines for the Clinical Management of Opioid Use Disorder developed by the BC Centre on Substance Use (BCCSU).

To support these new opioid agonist treatment options, Professional Practice Policy-66 now includes policy guides for Buprenorphine/Naloxone Maintenance Treatment and Slow Release Oral Morphine Maintenance Treatment. The existing policy guide for Methadone Maintenance Treatment continues to be in effect.  

The new BCCSU guidelines recommend buprenorphine/naloxone as the preferred first-line opioid agonist treatment (OAT) for opioid use disorder. Methadone remains a first line option when buprenorphine/naloxone is contraindicated or unfeasible, and slow-release oral morphine may be used  when both the first and second-line treatments are ineffective. This guideline will serve as the provincial clinical practice guideline for all clinicians who wish to prescribe oral OAT to patients with opioid use disorders.

The policy amendments and two new guides are in effect as of January 1, 2018. 


Professional Practice Policy-66: Opioid Agonist Treatment

Opioid Agonist Treatment Guides
PPP-66 Policy Guide: Buprenorphine/Naloxone Maintenance Treatment (2018) 
PPP-66 Policy Guide: Methadone Maintenance Treatment (2013)
PPP-66 Policy Guide: Slow Release Oral Morphine Maintenance (SROM) Treatment (2018) 
 
Resources